you may also like
RenSuper Biologics™ Autoimmune Disease Series | Part 1
Autoimmune diseases—including asthma, inflammatory bowel disease (IBD), and psoriasis—are highly complex, driven by dynamic interactions among immune cells, tissues, and signaling pathways. For decades, drug discovery focused on blocking single inflammatory pathways (e.g., TNF, IL-17, IL-23), which revolutionized care but often falls short of long-term disease control due to patient non-response, incomplete remission, or loss of efficacy over time (Roda et al., 2016; Taylor et al., 2022).
Because the immune system is deeply interconnected, single-target therapies are increasingly limited by biological redundancy, compensatory signaling, and heterogeneous, dynamic disease evolution (Chan & Carter, 2010).
To overcome these hurdles and achieve durable remission, the field is shifting from transient cytokine suppression to active immune network modulation (Mingueneau et al., 2024). Researchers aim to actively "reset" the immune system and restore long-term homeostasis by:
Although these approaches employ different molecular strategies, they share a common objective: achieving more coordinated regulation of complex immune networks while maintaining normal immune function.
The Oncostatin M receptor (OSMR) is an emerging immune regulatory hub in autoimmune diseases, tissue remodeling and fibrosis (West et al., 2017). Targeting OSMR enables simultaneous blockade of OSM and IL-31 signaling, representing a receptor-level approach to modulate interconnected inflammatory pathways.
► Biocytogen’s Fully Human Anti-OSMR Blocking Antibody:
Together these advanced strategies represent a broader shift in autoimmune drug development:
From target biology toward network biology.
Because autoimmune diseases often require lifelong management rather than short-term intervention, therapeutic success depends on achieving durable control while maintaining long-term safety. Developing antibody therapeutics for these chronic conditions therefore requires more than identifying disease-relevant targets—it requires integrated consideration of molecular design, pharmacology, and patient needs over years of treatment.
Together, these challenges highlight the need for advanced discovery platforms capable of delivering high-quality antibody candidates optimized for complex, long-term therapeutic applications.
Powered by our proprietary fully human RenMice® platform, Biocytogen has generated 100+ autoimmune disease antibody programs designed to address diverse inflammatory pathways.
Through integrated platforms including RenMab®, RenLite®, and RenNano®, we enable the discovery and development of high-affinity therapeutic antibodies across multiple modalities, including monoclonal antibodies, bispecific antibodies, bispecific ADCs, and VHH-based therapeutics.
Our autoimmune antibody portfolio spans multiple indications, including asthma, psoriasis, atopic dermatitis, systemic lupus erythematosus, rheumatoid arthritis, and transplant rejection, with off-the-shelf programs available to accelerate therapeutic development.
► Explore selected fully human antibody assets for autoimmune and inflammatory diseases below.
► More autoimmune antibody assets: https://biocytogen.com/drug-development/autoimmune-assets
► Browse our library for more: https://biocytogen.com/drug-development/inflammation-autoimmunity
The future of autoimmune drug development will increasingly be defined not only by the discovery of new targets, but more importantly by a deeper understanding of how immune pathways interact and the ability to design therapies that restore balance across these networks. Our programs and platform support researchers to rapidly evaluate therapeutic targets and engineer for advanced formats, including bispecific and multispecific antibodies.
In the next articles of this series, we will explore how this paradigm shift is reshaping therapeutic antibody strategies in specific diseases.
Stay tuned!
Immune network modulation is an emerging therapeutic strategy that aims to regulate multiple interconnected immune pathways rather than inhibiting a single cytokine or receptor. The goal is to achieve more durable disease control while preserving protective immune function.
Although biologics targeting TNF, IL-17, IL-23 and IL-4Ra have transformed treatments, many patients still experience primary non-response, secondary loss of response or incomplete remission. Autoimmune diseases are driven by interconnected immune networks, making single-target inhibition insufficient in some cases.
Bispecific antibodies can simultaneously engage two complementary biological pathways within a single molecule. This approach may help address pathway redundancy and compensatory signaling, making them promising modality for next-generation opportunities.
Unlike therapies for acute diseases, autoimmune biologics are often administered for years. Developers much balance long half-life, molecular stability, low immunogenicity, durable efficacy and preservation of normal immune function.
Biocytogen's RenSuper Biologics™ provides off-the-shelf access to a large portfolio of fully human antibody sequences generated from Biocytogen’s proprietary RenMice® platforms, enabling researchers to rapidly evaluate therapeutic targets and engineer for advanced formats, including bispecific and multispecific antibodies.
► Additional Resources:
► References:
